Mass Tort brief
Infant Formula Payouts and High Court Talc Framework
Abbott settles preterm formula claims while UK courts narrow Johnson & Johnson talc litigation.
Mass Tort
Abbott's $670M settlement sets a costly valuation benchmark for infant formula litigation, leaving UK-listed Reckitt exposed as federal trials begin.
BackgroundPreterm infant formula lawsuits allege that specialized cow's milk-based formulas increase the risk of necrotizing enterocolitis (NEC) in premature babies. Reckitt Benckiser acquired Mead Johnson in 2017, inheriting its infant nutrition product liability claims.
- Abbott settled ~2,000 claims alleging its preterm formula caused necrotizing enterocolitis, dropping its $495M verdict appeal to clear historical liability.
- Reckitt Benckiser's Mead Johnson faces the first federal MDL bellwether trial in Illinois, testing corporate liability for UK investor dockets.
- More than 825 lawsuits remain consolidated in federal MDL 3026 alongside thousands in state dockets, maintaining heavy litigation exposure across the industry.
Mass Tort
The High Court's 2028 trial framework trims weak claims and narrows the UK talc litigation strictly down to core scientific causation.
BackgroundGroup Litigation Orders allow English courts to manage multi-party claims sharing common questions of law or fact. Thousands of UK consumers allege that asbestos contamination in J&J baby powder caused mesothelioma and ovarian cancer.
- Mrs Justice Hill DBE ordered managed discontinuance for ~1,000 of 1,964 original UK claimants, stripping out claims lacking evidence of exposure.
- Stage 1 generic trial issues will examine asbestos presence in mineral talc and testing reliability, establishing baseline scientific standards.
- The mid-2028 trial will deliver binding legal findings for all remaining UK group action claimants, defining final liability scope for English courts.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
